LLY vs MAR: Which Is the Better Buy?

Side-by-side comparison of Eli Lilly and Company and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-20.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction Grade A High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$366.24
-3.4% upside to fair value
Med Conviction Grade C
QuantHub Verdict
LLY has more upside to fair value (+31.7%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric LLY MAR
Current Price $1,179.09 $366.24
Fair Value Estimate $1,552.32 $353.64
Upside to Fair Value +31.7% -3.4%
Market Cap $1,110.4B $96.6B
Forward P/E
EV / EBITDA 34.3x 23.8x
Price / Sales 14.6x 3.7x
Price / FCF 77.7x 31.6x
Revenue Growth YoY +55.5% +6.2%
Gross Margin 83.5% 21.4%
Operating Margin 45.9% 16.0%
Return on Equity 101.3% -74.1%
Dividend Yield 0.55% 0.75%
FCF Yield 1.29% 3.17%
Analyst Consensus Strong Buy Hold
Investment Thesis
LLY — Eli Lilly and Company
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
MAR — Marriott International, Inc.
Marriott International is a global asset-light hotel franchisor, manager and licensor whose high-quality brands, nearly 283 million Bonvoy members, more than 9,900 properties across 146 countries and record 4,107-property development pipeline create meaningful network, distribution and brand advantages. Q1 2026 demonstrated resilient underlying fee economics: adjusted revenue excluding cost-reimb…
Accumulation Zones
Metric LLY MAR
Zone Low $1,164.24 $265.23
Zone High $1,319.47 $300.59
In Buy Zone? Yes No
← LLY Research    MAR Research →    All Research